ARA-290 16mg

Description

ARA-290 Research Topics:

1. 1. Neuropathic Pain Relief & Nerve Repair:

      In both sarcoidosis and diabetic neuropathy, ARA‑290 significantly reduced neuropathic pain, improved corneal nerve fiber density, and enhanced nerve regeneration. [1]

   2. Anti‑Inflammatory Tissue Protection:

      Through activation of the innate repair receptor (EPOR/CD131), ARA‑290 reprograms pro-inflammatory environments into healing signals, reducing inflammation and promoting tissue repair in preclinical models. [2]

   3. Analgesia via TRPV1 Modulation:

      ARA‑290 directly inhibits TRPV1 ion channel activity in peripheral sensory neurons, reducing mechanical hypersensitivity in models of neuropathic pain. [2]

   4. Nephroprotective Effects:

      In cell models of cisplatin-induced kidney injury, ARA‑290 significantly decreased oxidative stress, inflammation (TNF‑α, IL‑1β, IL‑6), apoptosis, and DNA damage, demonstrating clear kidney protection. [3]

   5. Cardioprotective and Anti‑Frailty:

      Chronic ARA‑290 treatment in aged animal models reduced cardiac inflammation and fibrosis, improved mitochondrial function and autophagy, maintained ejection fraction, and mitigated age‐related frailty. [4]

   6. Neuroprotection in Ischemic Injury:

      ARA‑290 suppressed neuronal apoptosis and inflammation in cerebral ischemia models, highlighting its protective effects in stroke and related ischemic conditions. [5]

Reference Citation:

1. 1. Swartjes et al., 2014 – Mol Pain A small erythropoietin-derived peptide produces long-term relief of neuropathic pain and suppresses spinal microglia activation in rat nerve injury models. This preclinical study showed that Ara‑290 dose-dependently reduced mechanical and cold allodynia for up to 20 weeks and suppressed microglial activation—supporting its role in pain relief and neuroinflammation control. PMID: 24529189
   2. Zhang, W., Yu, G., & Zhang, M. (2016). ARA‑290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. Peptides, 76, 73–79.
      PMID: 26774587
   3. Ghassemi‑Barghi et al., 2023 – Inflammation Investigated cisplatin‑induced nephrotoxicity in vitro, ARA‑290 significantly reduced oxidative stress, inflammatory cytokines (TNF‑α, IL‑1β, IL‑6), DNA damage, and apoptosis markers (Caspase‑3, Bax), while increasing anti‑apoptotic Bcl‑2. This shows protection from toxic drug‑induced kidney injury. PMID: 36085231
   4. Winicki, N.M., Nanavati, A.P., Morrell, C.H., et al. (2023). A small erythropoietin-derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age-associated declines in heart function and prolongs healthspan. Frontiers in Cardiovascular Medicine, 9:1096887. PMID: 36741836
   5. Liang, J., et al. (2024). Erythropoietin‑derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke. CNS Neuroscience & Therapeutics. PMID: 38488446